Cancer-Driven Surge: AbbVie’s $10 Billion ‘ImmunoGen’ Deal Sparks an 83% Positive Uptick in Biotech Stocks
Introduction Cancer Industry Advances as AbbVie Plans $10.1 Billion Acquisition of Innovator ImmunoGen. This strategic move sent ripples through the ...
